StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a report released on Wednesday morning. The brokerage issued a sell rating on the medical research company’s stock.
OpGen Price Performance
Shares of NASDAQ:OPGN opened at $1.90 on Wednesday. The company’s fifty day moving average is $2.63 and its two-hundred day moving average is $4.05. OpGen has a 12-month low of $1.65 and a 12-month high of $38.40.
OpGen (NASDAQ:OPGN – Get Free Report) last posted its quarterly earnings results on Monday, July 8th. The medical research company reported $0.21 earnings per share for the quarter. OpGen had a negative return on equity of 1,827.76% and a negative net margin of 997.34%. The firm had revenue of $0.17 million for the quarter.
Institutional Trading of OpGen
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Recommended Stories
- Five stocks we like better than OpGen
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- Most Volatile Stocks, What Investors Need to Know
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- What is the Dow Jones Industrial Average (DJIA)?
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.